Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 200 Dongduk-Ro, Jung-Gu, Daegu 700-721, Korea.
Med Oncol. 2012 Jun;29(2):1179-85. doi: 10.1007/s12032-011-9926-8. Epub 2011 Apr 7.
To achieve successful therapeutic outcomes in chronic myeloid leukemia (CML), continuous and adequate imatinib (Gleevec(®), Glivec(®), Novartis Pharmaceuticals, Basel, Switzerland) dosing is essential. Here, we report a patient counseling program ("Care club", "Happy club" in Korea) performed to improve patient compliance with imatinib. From January 2006 to December 2008, patients diagnosed with chronic phase CML and taking imatinb were eligible for this retrospective study. A total of 114 patients from 4 centers in Korea were recruited at a 50:50 ratio for Happy club group versus non-Happy club group at each center. During 36-month follow-up, persistency (the number of days of imatinib prescribed versus 1 year) was higher in the Happy club group (98.2 ± 0.03%) than in the non-Happy club group (79.3 ± 0.16%, P = 0.001), whereas dose compliance (miligrams of imatinib that were actually taken versus miligrams that should have been taken) was not different between two groups; 96.5 ± 0.6% and 96.6 ± 0.7% in the Happy club and non-Happy club (P = 0.958). Overall compliance (the product of persistency and dose compliance) improved in the Happy club group (93.0 ± 2.3%) compared with the non-Happy club group (76.2 ± 7.4%, P = 0.001). The patient counseling program was efficient especially in patients who needed high-dose imatinib (>400 mg/day), and overall compliance was 87.8 ± 6.0% in the Happy club group versus 65.5 ± 16.1% in the non-Happy club group (P = 0.017). In conclusion, the patient counseling program was effective in persisting imatinib medication, resulting in the improvement of overall compliance.
为了在慢性髓性白血病（CML）中实现成功的治疗效果，持续且充分的伊马替尼（格列卫®，Glivec®，诺华制药，巴塞尔，瑞士）剂量是至关重要的。在这里，我们报告了一项旨在提高患者对伊马替尼依从性的患者咨询计划（“关怀俱乐部”，韩国的“快乐俱乐部”）。从 2006 年 1 月至 2008 年 12 月，在韩国的 4 个中心中，符合慢性期 CML 诊断并服用伊马替尼的患者有资格参加这项回顾性研究。每个中心的快乐俱乐部组和非快乐俱乐部组的比例为 50:50，共有 114 名患者入选。在 36 个月的随访期间，快乐俱乐部组（98.2 ± 0.03%）的持续用药率（开具的伊马替尼天数与 1 年相比）高于非快乐俱乐部组（79.3 ± 0.16%，P = 0.001），而两组之间的剂量依从性（实际服用的伊马替尼毫克数与应服用的毫克数之比）无差异；快乐俱乐部组为 96.5 ± 0.6%，非快乐俱乐部组为 96.6 ± 0.7%（P = 0.958）。快乐俱乐部组的总体依从性（持续用药率和剂量依从性的乘积）（93.0 ± 2.3%）优于非快乐俱乐部组（76.2 ± 7.4%，P = 0.001）。该患者咨询计划在需要高剂量伊马替尼（>400mg/天）的患者中尤其有效，快乐俱乐部组的总体依从性为 87.8 ± 6.0%，而非快乐俱乐部组为 65.5 ± 16.1%（P = 0.017）。总之，患者咨询计划在坚持伊马替尼治疗方面是有效的，从而提高了总体依从性。
